No 340B Savings for Transgender Care Act

Bill 119 HR 2197, also known as the "Preventing Misuse of 340B Program Savings Act," aims to restrict 340B covered entities from using their savings for certain medical procedures, specifically sex reassignment surgeries and hormonal therapies. The 340B program allows certain healthcare providers, such as hospitals and clinics that serve low-income populations, to purchase prescription drugs at discounted prices.

The bill seeks to prevent these entities from using their savings from the 340B program to fund sex reassignment surgeries and hormonal therapies, as well as other purposes that may not align with the original intent of the program. Supporters of the bill argue that the 340B program should be used to provide essential medications and services to underserved communities, rather than funding elective procedures.

Opponents of the bill argue that it unfairly targets transgender individuals and restricts their access to necessary medical care. They argue that healthcare decisions should be made between a patient and their healthcare provider, without government interference. Overall, Bill 119 HR 2197 raises important questions about the use of savings from the 340B program and the role of government in regulating healthcare services. It will be important to monitor the progress of this bill and consider the potential impact on both healthcare providers and patients.